Company: Switzerland Omics switzerlandomics.ch
Product: Genomic Vault is secure custody and controlled access for genomes. Private by default. Delivered professionally on demand (see product page).
Founders: 12 years of PhD+ experience in applied genomics and statistical modelling. Backed by federal funding and national-scale studies across UZH, EPFL, and ETH Zurich.
Stage: Pre-incorporation.
Request: CHF xxx for Swiss hosting, legal setup, and scaling infrastructure.
The gap
Genomics is now mainstream, yet data fragments across providers and time. There is no accountable custodian or standard supply chain. Families pay again for fresh work and care is delayed.
Our solution
Genomic Vault keeps one secure record under the patient’s control.
- Long-term (+10 year) custody of raw files and derived sets in clinical formats
- Private by default with explicit, logged sharing to named recipients
- Standard delivery every time for clinics and research groups
- SPHN-compliant RDF metadata for hospital integration
- Swiss residency, encryption in transit and at rest, full audit trails
- Independent from analysis and from secondary data use
Vision
A patient-owned supply chain for genomic data. Trusted custody for individuals, clinics, research groups, and national programmes. Better health insurance and better healthcare without disclosing genetic results.
Traction
- Production portal live with account-based consent and logged sharing
- SPHN RDF metadata and TTL exports ready for hospital systems
- Rare disease special service running with selected cases
- Documentation and legal framework published
Product maturity
- Built on a decade of Swiss genomics programmes
- Security controls aligned to ISO 27001, 27017, 27018 roadmap
- Clear roles for controller and processor in institutional deployments
Finance model
Our finance model combines direct custody revenue with long-term security through a Swiss federally guaranteed reserve bond. Sequencing partners deliver data directly into Genomic Vault, where each genome is preserved for a 10-year cycle under the same structure for institutions and private individuals alike. A portion of all fees funds the reserve bond, ensuring continuity and data protection even in the event of operational or market disruption. Over time, insurers will subsidise access as part of preventive healthcare funding, maintaining full privacy while reducing healthcare costs. This creates a transparent, stable, and legally grounded model for national-scale genomic custody.
Scientific and regulatory foundation
- revDSG, HGTA, GDPR alignment
- Independent development with public documentation
- Auditable code, data, and finances
- Clear path to ISO 27001, 27017, 27018. Diagnostic standards considered only if scope expands
Impact
- Patients: privacy, custody, and fast access when needed
- Clinics and research: the same dataset delivered professionally every time
- Insurers: lower claim volatility by funding access, without receiving genomic profiles
Who it is for
- Clinical laboratories and variant pipelines
- Research groups and biobanks
- Pharmacogenomics and trial sponsors
- Health insurers seeking compliant prevention programmes
Intellectual property
Genomic Vault is grounded in insider knowledge of how Swiss research, law, and funding systems operate. It reflects the trust, precision, and shared responsibility that define this community. As with Switzerland Omics’ algorithms, some critical components are protected intellectual property, but the priority remains transparency and public trust. What matters most is that the system aligns with the way Swiss institutions and researchers already work, ensuring credibility and long-term acceptance.
